miRNA-99b-5p suppresses liver metastasis of colorectal cancer by down-regulating mTOR

Oncotarget

Volumn 6, Issue 27, 2015, Pages 24448-24462

  Li, Wenhua ^a,b   Chang, Jinjia ^a,b   Wang, Shanshan ^a,b   Liu, Xinyang ^a,b   Peng, Junjie ^a,b   Huang, Dan ^a,b   Sun, Menghong ^a,b   Chen, Zhiyu ^a,b   Zhang, Wen ^a,b   Guo, Weijian ^a,b   Li, Jin ^a,b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

Colorectal carcinoma; Liver metastasis; MiR 99b 5p; MTOR

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; MICRORNA; MICRORNA 99B 5P; UNCLASSIFIED DRUG; 3' UNTRANSLATED REGION; ANTINEOPLASTIC AGENT; MIRN99 MICRORNA, HUMAN; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

ADULT; AGED; ARTICLE; CANCER STAGING; CELL MIGRATION; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HUMAN; HUMAN TISSUE; LIVER METASTASIS; LUCIFERASE ASSAY; MALE; OVERALL SURVIVAL; PROTEIN TARGETING; UPREGULATION; 3' UNTRANSLATED REGION; CELL MOTION; CELL PROLIFERATION; CELL SURVIVAL; CHEMISTRY; COLORECTAL TUMOR; GENE EXPRESSION REGULATION; GENETICS; HCT 116 CELL LINE; LIVER TUMOR; METABOLISM; METASTASIS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SECONDARY; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

3' UNTRANSLATED REGIONS; ADULT; AGED; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; COLORECTAL NEOPLASMS; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HCT116 CELLS; HUMANS; LIVER NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; TOR SERINE-THREONINE KINASES; UP-REGULATION;

EID: 84943421429     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4423     Document Type: Article

References (43)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer Statistics, 2014. CA Cancer J Clin. 2014;64:9-29.
2. Shanghai municipal center for disease control and prevention:Shanghai Cancer Report 2007. Shanghai J Prev Med. 2010;22:399-400.
3. Adam R. Chemotherapy and surgery:new perspectives on the treatment of unresectable liver metastases. Ann Oncol. 2003;14 Suppl 2:ii13-16.
4. Van den Eynde M, Hendlisz A. Treatment of colorectal liver metastases:a review. Rev Recent Clin Trials. 2009;4: 56-62.
5. Adam R, De Gramont A, Figueras J, Guthrie A, Kokudo N, Kunstlinger F, Loyer E, Poston G, Rougier P, RubbiaBrandt L, Sobrero A, Tabernero J, Teh C, et al. The oncosurgery approach to managing liver metastases from colorectal cancer:a multidisciplinary international consensus. Oncologist. 2012;17:1225-1239.
6. Adam R, Haller DG, Poston G, Raoul JL, Spano JP, Tabernero J, Van Cutsem E. Toward optimized front-line therapeutic strategies in patients with metastatic colorectal cancer-an expert review from the International Congress on Anti-Cancer Treatment (ICACT) 2009. Ann Oncol. 2010; 21:1579-1584.
7. Geng L, Chaudhuri A, Talmon G, Wisecarver JL, Are C, Brattain M, Wang J. MicroRNA-192 suppresses liver metastasis of colon cancer. Oncogene. 2013;33:5332-5340.
8. Hur K, Toiyama Y, Takahashi M, Balaguer F, Nagasaka T, Koike J, Hemmi H, Koi M, Boland CR, Goel A. MicroRNA-200c modulates epithelial-to-mesenchymal transition (EMT) in human colorectal cancer metastasis. Gut. 2013;62:1315-1326.
9. Liao WT, Ye YP, Zhang NJ, Li TT, Wang SY, Cui YM, Qi L, Wu P, Jiao HL, Xie YJ, Zhang C, Wang JX, Ding YQ. MicroRNA-30b functions as a tumour suppressor in human colorectal cancer by targeting KRAS, PIK3CD and BCL2. J Pathol. 2014;232:415-427.
10. Ma Y, Zhang P, Wang F, Zhang H, Yang Y, Shi C, Xia Y, Peng J, Liu W, Yang Z Qin H. Elevated oncofoetal miR-17-5p expression regulates colorectal cancer progression by repressing its target gene P130. Nat Commun. 2012;3: 1291.
11. Slaby O, Svoboda M, Fabian P, Smerdova T, Knoflickova D, Bednarikova M, Nenutil R, Vyzula R. Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer. Oncology. 2007;72:397-402.
12. Yang MH, Yu J, Chen N, Wang XY, Liu XY, Wang S, Ding YQ. Elevated MicroRNA-31 Expression Regulates Colorectal Cancer Progression by Repressing Its Target Gene SATB2. PloS One. 2013;8:e85353.
13. Yuan K, Xie K, Fox J, Zeng H, Gao H, Huang C, Wu M. Decreased levels of miR-224 and the passenger strand of miR-221 increase MBD2, suppressing maspin and promoting colorectal tumor growth and metastasis in mice. Gastroenterology. 2013;145:853-864 e859.
14. Zhang JX, Song W, Chen ZH, Wei JH, Liao YJ, Lei J, Hu M, Chen GZ, Liao B, Lu J, Zhao HW, Chen W, He YL, et al. Prognostic and predictive value of a microRNA signature in stage II colon cancer:a microRNA expression analysis. Lancet Oncol. 2013;14:1295-1306.
15. Zhang L, Pickard K, Jenei V, Bullock MD, Bruce A, Mitter R, Kelly G, Paraskeva C, Strefford J, Primrose J, Thomas GJ, Packham G, Mirnezami AH. miR-153 supports colorectal cancer progression via pleiotropic effects that enhance invasion and chemotherapeutic resistance. Cancer Res. 2013;73:6435-6447.
16. Ji D, Chen Z, Li M, Zhan T, Yao Y, Zhang Z, Xi J, Yan L, Gu J. MicroRNA-181a promotes tumor growth and liver metastasis in colorectal cancer by targeting the tumor suppressor WIF-1. Mol Cancer. 2014;13:86.
17. Chen DL, Wang ZQ, Zeng ZL, Wu WJ, Zhang DS, Luo HY, Wang F, Qiu MZ, Wang DS, Ren C, Wang FH, Chiao LJ, Pelicano H, et al. Identification of microRNA-214 as a negative regulator of colorectal cancer liver metastasis by way of regulation of fibroblast growth factor receptor 1 expression. Hepatology. 2014;60:598-609.
18. Francipane MG, Lagasse E. mTOR pathway in colorectal cancer:an update. Oncotarget. 2014;5:49-66.
19. Tsukerman P, Yamin R, Seidel E, Khawaled S, Schmiedel D, Bar-Mag T, Mandelboim O. MiR-520d-5p directly targets TWIST1 and downregulates the metastamiR miR-10b. Oncotarget. 2014;5:12141-12150.
20. Volinia S, Nuovo G, Drusco A, Costinean S, Abujarour R, Desponts C, Garofalo M, Baffa R, Aeqilan R, Maharry K, Sana ME, Di Leva G, Gasparini P, et al. Pluripotent stem cell miRNAs and metastasis in invasive breast cancer. J Natl Cancer Inst. 2014;106. pii:dju324. doi:10.1093/jnci/dju324.
21. Pareek CS, Smoczynski R, Tretyn A. Sequencing technologies and genome sequencing. J Applied Genet. 2011;52:413-435.
22. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487:330-337.
23. Vakiani E, Janakiraman M, Shen R, Sinha R, Zeng Z, Shia J, Cercek A, Kemeny N, D'Angelica M, Viale A, Heguy A, Paty P, Chan TA, et al. Comparative genomic analysis of primary versus metastatic colorectal carcinomas. J Clin Oncol. 2012;30:2956-2962.
24. Liu SG, Qin XG, Zhao BS, Qi B, Yao WJ, Wang TY, Li HC, Wu XN. Differential expression of miRNAs in esophageal cancer tissue. Oncol Lett. 2013;5:1639-1642.
25. Srivastava A, Goldberger H, Dimtchev A, Ramalinga M, Chijioke J, Marian C, Oermann EK, Uhm S, Kim JS, Chen LN, Li X, Berry DL, Kallakury BV, et al:MicroRNA profiling in prostate cancer-the diagnostic potential of urinary miR-205 and miR-214. PloS One. 2013;8:e76994.
26. Feber A, Xi L, Pennathur A, Gooding WE, Bandla S, Wu M, Luketich JD, Godfrey TE, Litle VR. MicroRNA prognostic signature for nodal metastases and survival in esophageal adenocarcinoma. Ann Thorac Surg. 2011;91: 1523-1530.
27. Wu W, Lin Z, Zhuang Z, Liang X. Expression profile of mammalian microRNAs in endometrioid adenocarcinoma. Eur J Cancer Prev. 2009;18:50-55.
28. Sun D, Lee YS, Malhotra A, Kim HK, Matecic M, Evans C, Jensen RV, Moskaluk CA, Dutta A. miR-99 family of MicroRNAs suppresses the expression of prostate-specific antigen and prostate cancer cell proliferation. Cancer Res. 2011;71:1313-1324.
29. Kang J, Lee SY, Kim YJ, Park JY, Kwon SJ, Na MJ, Lee EJ, Jeon HS, Son JW. microRNA-99b acts as a tumor suppressor in non-small cell lung cancer by directly targeting fibroblast growth factor receptor 3. Exper Ther Med. 2012;3:149-153.
30. Xin JX, Yue Z, Zhang S, Jiang ZH, Wang PY, Li YJ, Pang M, Xie SY:miR-99 inhibits cervical carcinoma cell proliferation by targeting TRIB2. Oncology Lett. 2013;6: 1025-1030.
31. Jin Y, Tymen SD, Chen D, Fang ZJ, Zhao Y, Dragas D, Dai Y, Marucha PT, Zhou X. MicroRNA-99 family targets AKT/mTOR signaling pathway in dermal wound healing. Plos One. 2013;8:e64434.
32. Wei F, Liu Y, Guo Y, Xiang A, Wang G, Xue X, Lu Z. miR-99b-targeted mTOR induction contributes to irradiation resistance in pancreatic cancer. Mol Cancer. 2013;12:81.
33. Fingar DC, Salama S, Tsou C, Harlow E, Blenis J. Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev. 2002. 16:1472-1487.
34. Murugan AK, Alzahrani A, Xing M. Mutations in critical domains confer the human mTOR gene strong tumorigenicity. J Biol Chem. 2013;288:6511-6521.
35. Cao Y, Liu X, Lu W, Chen Y, Wu X, Li M, Wang XA, Zhang F, Jiang L, Zhang Y, Hu Y5, Xiang S1, Shu Y, et al. Fibronectin promotes cell proliferation and invasion through mTOR signaling pathway activation in gallbladder cancer. Cancer Lett. 2015. pii:S0304-3835(15)00087-7. doi:10.1016/j.canlet.2015.01.041. [Epub ahead of print].
36. Singh P, Agarwal N, Pal SK. Sequencing Systemic Therapies for Metastatic Kidney Cancer. Curr Treat Options Oncol. 2015. [Epub ahead of print].
37. Jiang F, Chen L, Yang YC, Wang XM, Wang RY, Li L, Wen W, Chang YX, Chen CY, Tang J, Liu GM, Huang WT, Xu L, et al. CYP3A5 Functions as a Tumor Suppressor in Hepatocellular Carcinoma by Regulating mTORC2/Akt Signaling. Cancer Res. 2015. pii:canres.1589.2014. [Epub ahead of print].
38. Zhang C, Yuan XR, Li HY, Zhao ZJ, Liao YW, Wang XY, Su J, Sang SS, Liu Q. Anti-Cancer Effect of Metabotropic Glutamate Receptor 1 Inhibition in Human Glioma U87 Cells:Involvement of PI3K/Akt/mTOR Pathway. Cell Physiol Biochem. 2015;35:419-432.
39. Battelli C, Cho DC. mTOR inhibitors in renal cell carcinoma. Therapy. 2011;8:359-367.
40. Liu L, Zhang W, Li W, Lv F, Xia Z, Zhang S, Liu W, Zandvliet AS, Waajen S, Zhang LX, Yan L, Li J. A phase I study of ridaforolimus in adult Chinese patients with advanced solid tumors. J Hematol Oncol. 2013;6:48.
41. Blagosklonny MV. Rapalogs in cancer prevention:antiaging or anticancer? Cancer biology & therapy. 2012; 13:1349-1354.
42. Roulin D, Cerantola Y, Dormond-Meuwly A, Demartines N, Dormond O. Targeting mTORC2 inhibits colon cancer cell proliferation in vitro and tumor formation in vivo. Mol Cancer. 2010;9:57.
43. Zhang YJ, Dai Q, Sun DF, Xiong H, Tian XQ, Gao FH, Xu MH, Chen GQ, Han ZG, Fang JY. mTOR signaling pathway is a target for the treatment of colorectal cancer. Ann Surg Oncol. 2009;16:2617-2628.